Aim: To discuss the use of 6-monthly buprenorphine implants for maintenance treatment of opioid use disorder and the potential clinical implications if approved in Australia. Data sources: MEDLINE, Embase, Cumulative Index to Nursing and Allied Health Literature and Web of Science were searched using the key terms 'buprenorphine implant', 'opioid dependence' and 'Probuphine' for articles published between January 2000 and August 2017. Study selection: English-language, peer-reviewed articles were eligible for inclusion if they evaluated the effectiveness of buprenorphine implants for opioid dependence. Results: After implantation, an initial pulse is followed by an exponential decline to a non-fluctuating buprenorphine plasma concentration sustained over 6 months. In a double-blind randomised controlled trial, buprenorphine implants were non-inferior to low-to-moderate doses of sublingual buprenorphine (SLB) in clinically stable abstinent patients, with 6-month abstinence being superior to SLB. Adverse effects are comparable to established buprenorphine preparations, although local issues from surgical implantation and explantation procedures appear commonplace, necessitating risk evaluation and mitigation strategies. No studies compared implantable buprenorphine to methadone, which retains patients in therapy more effectively than SLB at a fixed and low dose. Implants offer potential cost savings over SLB, with biannual dosing and tamper-proof characteristics poised to address issues such as poor adherence, misuse, diversion and inadvertent exposures. Conclusion: Buprenorphine implants have expanded the therapeutic repertoire for opioid use disorder, offering greater opportunity for treatment individualisation. Implants are currently indicated for a small subset of patients who have first demonstrated clinical stability on low-to-moderate doses of SLB. Preliminary data highlight their potential to hypothetically supersede existing treatment modalities in appropriately selected candidates.
INTRODUCTION
Opioid use disorder (OUD) is a chronic, relapsing disease in which cognitive, behavioural and physiological symptoms drive persistent opioid use despite the onset of clinically significant sequelae. 1 Chronic opioid administration incites several neurobiological changes, with long-lasting alterations in opioid receptor (OR) expression and signal transduction, as well as changes in GABAergic neurotransmission within the mesocorticolimbic system. The disorder manifests as compulsive drug-seeking and drug-taking behaviour, reinforced by both physiological and psychological dependency. It contributes heavily to the global burden of disease and carries a prominent risk of fatal overdose. [2] [3] [4] [5] Effective management of this complex condition requires a sound understanding of the neurobiology and underlying social context of each individual patient. As such, combining pharmacological and psychosocial interventions is routine practice. 2 Oral and sublingual medications such as methadone and buprenorphine are the mainstay of pharmacotherapy, and act as substitutes for illicit and harmful opioids to attenuate cravings and withdrawal without consequent euphoria. Opioid substitution therapy (OST) reduces illicit opioid use more effectively than psychosocial intervention or placebo alone, stemming OUD-associated morbidity and mortality.
Buprenorphine is a semisynthetic partial agonist with high affinity and protracted dissociation at the l-OR, and antagonism at the d-and j-ORs. 6 Its partial agonist activity is subject to a ceiling effect, translating to low overdose potential even at high doses. It is associated with less subjective euphoria and physical dependence, as well as less severe withdrawal than full agonists. Such properties enable buprenorphine to antagonise the effect of exogenous opioid agonists and deter illicit use. 7, 8 Although buprenorphine is a well-established OST, there are several acknowledged limitations to its sublingual (SL) administration. 4 Current OST arrangements require frequent clinical contact, with patients typically adhering to daily supervised dosing regimens, necessitating the taxing day-to-day logistics of time and travel that challenge adherence. 5 Non-adherence jeopardises desirable clinical outcomes and increases the likelihood of relapse. The provision of convenient 'take-away' doses remains controversial due to inadvertent exposures and the potential for diversion to 'street' markets, despite the addition of naloxone to formulations to deter intravenous administration (by precipitating withdrawal). 9, 10 This is compounded in rural areas, with fewer registered prescribers hampering regular clinical contact.
11,12
The imperfections of current pharmacotherapies for OUD have necessitated innovative strategies to refine management. A recent advancement in OST has been the introduction of a sustained-release buprenorphine matrix implant (Probuphine, Braeburn Pharmaceuticals Inc., Princeton, New Jersey, USA), which received US Food and Drug Administration (FDA) approval in May 2016 for patients aged 16-65 years who have demonstrated prolonged clinical stability on low-to-moderate doses (≤8 mg/day) of sublingual buprenorphine (SLB). 13 Buprenorphine implants are designed to optimise adherence, improve rates of opioid abstinence and reduce public health liabilities, such as diversion, misuse and inadvertent exposures. 10 For select patients, semi-annual administration could significantly reduce the frequency of clinical contact required during treatment while also improving adherence. The maintenance of a consistent plasma buprenorphine concentration is a key feature of this emerging technology, aiming to reduce the likelihood and severity of cravings and withdrawal symptoms. This review aims to provide an overview of the clinical utility of implantable buprenorphine for the maintenance treatment of OUD, focusing on its ability to surmount the shortcomings of existing treatment strategies and the potential clinical implications if approved for use in Australia. The review is divided into two sections: (1) general information (administration, pharmacokinetics, interactions and financial considerations); and (2) review of clinical trial data.
GENERAL INFORMATION Dosage and Administration Procedure
Each 2.5-mm 9 26-mm ethylene vinyl acetate (EVA) implant contains 80 mg buprenorphine hydrochloride (equivalent to 74.2 mg buprenorphine). Under local anaesthesia, four implants are placed into the subdermal space through a single 2.5-to 3-mm incision in the inner aspect of the upper arm to achieve plasma concentrations in the range of 0.5-1.0 ng/mL.
14 After insertion, the implant site should be reviewed 1 week later for signs of infection or other complications. Implants should be removed after 6 months, followed by the insertion of a subsequent course into the contralateral arm if indicated. Reinsertion into prior administration sites or sites other than the upper arm has not been investigated. The absence of clinical experience beyond one 6-month course in each arm currently dissuades further use, prompting transition back to SLB.
Pharmacokinetics
Buprenorphine release is dependent on the rate of dissolution and passive diffusion through the EVA copolymer matrix. 15 Probuphine pharmacokinetics are consistent across all human clinical trials. 14, [16] [17] [18] Maximal plasma concentrations are achieved within 24 h of administration and decline exponentially to a low, non-fluctuating concentration from week 4 to week 24 eliminating typical peaks and troughs associated with SL administration. Following the insertion of four implants, the relative bioavailability on day 28 is 31% of that achieved by 16 mg SLB daily at steady state. Maximum concentrations achieved on day one are lower than that of 16 mg SLB daily and remain lower over 24 weeks, highlighting lower relative exposure to the drug. 19 The average steady state concentration in one trial was 0.94 ng/ mL, approximating to 1-1.3 mg/day. 17 The terminal half-life of buprenorphine upon removal (explantation) averages less than 24 h. 16 Regardless of administration route, buprenorphine undergoes glucuronidation and Ndealkylation to form its conjugate and norbuprenorphine, respectively. Parent N-dealkylation is principally cytochrome (CYP) 3A4-mediated. Norbuprenorphine further conjugates with glucuronic acid. Buprenorphine is primarily excreted in the faeces.
Drug Interactions
Buprenorphine drug interactions resulting from subdermal implant administration have not been specifically evaluated, although are unlikely to differ from existing administration routes. Cytochrome activity, particularly CYP3A4, can affect plasma concentrations of SLB and may similarly affect implantable buprenorphine concentrations, necessitating monitoring for over-and undertreatment. 19 Alcohol and other central nervous system (CNS) depressants (such as benzodiazepines) interact pharmacodynamically, resulting in altered cognition, heightened sedation and potentially fatal respiratory depression. 21, 22 Serotonin syndrome may transpire when coadministered with serotonergic agents. 22 Aside from presenting theoretical challenges for opioid analgesia, buprenorphine may also precipitate withdrawal in opioid-dependent patients through the displacement of a full agonist. 19 
Financial Considerations
A Probuphine implant kit (containing four implants) costs approximately US$4950, and is sufficient for 6 months of maintenance. 23 This is more expensive than Suboxone SL film, Indivior UK Limited, North Chesterfield, VA, USA (US$2660), generic SLB tablets (US$1672) and generic SL buprenorphine/naloxone tablets (US $2814), but less expensive than an extended-release naltrexone depot injection (US$7680) available in the US over 6 months.
23,24
Although implantable buprenorphine is more expensive than most alternatives, a recent cost-effectiveness study associated its use with lower total expenditure (-US$4386), increased quality adjusted life years (QALY; +0.031) and favourable incremental net monetary benefit at all willingness-to-pay thresholds compared with SLB. 25 The higher cost appears justified in light of lower emergency department and/or hospital expenditure (-US$8040) and criminality (-US$1212). The implant was cost-effective in 89% of probabilistic sensitivity analysis model replicates, and had a significantly higher net monetary benefit at US$50 000/QALY (US$20 783 vs US $15 007; p < 0.05). 25 However, inherent differences between the US and Australian healthcare systems may limit the generalisability of these pharmacoeconomic findings.
METHODS

Clinical Trials Search Methodology
Database searches of MEDLINE, Embase, Cumulative Index to Nursing and Allied Health Literature and Web of Science were performed using a combination of the key terms 'buprenorphine implant', 'opioid dependence' and 'Probuphine' for peer-reviewed articles published between January 2000 and August 2017. The search strategy initially identified 366 articles, which was reduced to 335 after duplicates were removed. After abstract screening, 307 articles were excluded, leaving 17 for full-text review. Further screening resulted in four key articles being reviewed: an initial dose-finding trial and three subsequent Phase III studies which serve to provide an understanding of the safety and efficacy of this new treatment offering. 14, [16] [17] [18] Reasons for article exclusion from the initial 17 were results featuring naltrexone implants for opioid dependence or buprenorphine studies not concerning implantable systems. Reference lists and citations of the retrieved literature were evaluated to identify additional sources for inclusion.
RESULTS
Efficacy
Following an initial dose-finding trial, 16 three Phase III trials have evaluated the efficacy of buprenorphine implants in subjects fulfilling Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM IV) criteria for a diagnosis of opioid dependence. 14, 17, 18 The primary outcome in these investigations was the reduction in illicit opioid use, as evidenced by urinalysis. A summary of these trials and their respective findings is presented in Table 1 that buprenorphine implants were non-inferior to SLB. In the same trial, post hoc analyses noted significantly lower cocaine use among those who received an active implant, versus placebo. 18 The initial application for FDA approval presented data from these two trials, although the extent of supplementary SLB required by active implant recipients suggested subtherapeutic dosing (https://www.fda.gov/newsevents/newsroom/pressa nnouncements/ucm503719.htm; accessed 9 January were of low incidence, and without deviation from the known safety profile of buprenorphine. 27 Minor implant site-related adverse effects, such as pain, erythema and pruritus, were mild and resolved without intervention. 14, 17, 18 A pooled summary of adverse effects reported by ≥2% of participants in the Phase III trials 19 is given in Table 2 . Over one-third of patients experienced at least one implant site-related adverse effect, with several patients reporting multiple coinciding effects over 24 weeks. These adverse effects dictated treatment cessation on only three occasions among active implant users (0.97% incidence rate). Precipitants included one case of intolerable pain and two cases of intolerable pain accompanied by infection. 17 There was no evidence of nerve damage, implant migration or any attempted or unscheduled implant removal by patients. Histopathologically, in vivo responses to the implants appear biologically appropriate, and assuage with time. 15 
DISCUSSION
The recent FDA approval of subdermal buprenorphine implants for the maintenance treatment of OUD is geared to support decision making for prescribers and optimise treatment outcomes for patients. At present, the implant is indicated for patients aged 16-65 years who have demonstrated clinical stability on low-tomoderate doses of SLB, as part of a holistic treatment program that includes counselling and psychosocial support. 28 The implant has evidence of efficacy in Significantly longer time to first evidence of illicit opioid use than SLB ≤8 mg (p = 0.04) Coagulopathy within 90 days Thrombocytopenia Absence of appropriate implant site BI = buprenorphine implant; CYP3A4 = cytochrome P450 3A4; PI = placebo implant; SL = sublingual; SLBNX = sublingual buprenorphine/naloxone; SLB = sublingual buprenorphine. a Mutual inclusion criteria: 18-65 years of age, DSM-IV opioid dependence; mutual exclusion criteria: AIDS, pregnancy, pain requiring opioid analgesia, coexisting dependence on substance other than opioids or nicotine, serum aspartate aminotransferase: alkaline phosphatase ratio ≥3 9 the upper limit of normal (ULN), bilirubin or creatinine ≥1.5 9 ULN. reducing illicit opioid use and increasing opioid abstinence compared with placebo and/or SLB over 24 weeks, although there is less certainty about its longer-term efficacy at this time. Three Phase III trials have evaluated buprenorphine implants in the management of OUD, although differences in design limit the generalisability of results to clinical practice. 14, 17, 18 The open-label comparator trial by Rosenthal et al.
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declared non-inferiority to SLB among new entrants to therapy, although a questionable non-inferiority margin and lack of blinding limits the strength of this finding.
29
A subsequent post hoc re-evaluation incorporating additional multiple sensitivity analyses in conjunction with more stringent parameters disfavouring implants maintained the original findings of non-inferiority in new entrants to therapy. 30 Findings from the pivotal doubleblind double-dummy trial of Rosenthal et al. 14 also demonstrated non-inferiority of the implant system to SLB, although in a different patient population to that addressed in early trials. In the study of Rosenthal et al., 14 patients were not only stable and abstinent, but predominantly Caucasian, employed, had at least a high school education and had a predilection for prescription rather than illicit opioids. It should be noted that efficacy data were drawn from trials enrolling subjects with a diagnosis of opioid dependence based on DSM-IV criteria. Extrapolating these findings to patients diagnosed under the current DSM-5 'opioid use disorder' 1 is imprecise, because only the moderate-severe subtype closely resembles that of the study cohorts. 31 With these considerations in mind, it is imperative that implants be trialled in broader populations diagnosed under the DSM-5 for more seamless integration into current practice. It should also be reinforced that the trials discussed herein were designed and financed by the manufacturer of the buprenorphine implants.
The semi-annual administration of buprenorphine implants eliminates the risks of non-adherence, because patients consider daily dosing of SLB arduous and restrictive. Although patient preference has not been gauged, anecdotal reports favour the implant over SLB. 16, 32 Reducing the logistic burdens of treatment may improve patient engagement in prosocial behaviours (e.g. employment, education, family responsibilities) as part of a comprehensive rehabilitation. From a health system perspective, less clinical contact per patient could increase clinician availability to newcomers. This is significant considering untreated patients, including those on long clinic waiting lists, remain at risk of harm and premature death. 33, 34 Although currently unverified, the lower clinical requirements of a 6-monthly buprenorphine injection could improve rural treatment rates and treatment retention. Retention in OST decreases mortality, improves social functioning, lowers drug-taking and improves quality of life. 3, 35 Over 24 weeks, retention rates as high as 65.7% were observed in active implant cohorts new to OST, 17 compared with retention rates of 38-78% reported in open-label and single-blind studies involving SLB, 4,36 with 55% retention displayed in a US office-based setting. 37 Poor retention may be associated with fluctuating plasma concentrations that inherently follow SL administration. 38 The much higher implant retention rate of 93.2% observed by Rosenthal et al. 14 is promising, although it should be noted that these recipients were stable for over 24 weeks prior to the intervention and that the SLB comparator arm was noninferior. Despite key differences pharmacokinetically, the significance of a steady plasma concentration has not been prospectively studied. Upon explant, the rapid termination kinetics of Probuphine confirm the absence of unintended drug reservoirs in situ. 15 This is desirable for patients requiring abrupt cessation due to adverse events. This is balanced by situations in which buprenorphine maintenance recipients require opioid analgesia in the acute setting, wherein continued drug release may oppose treatment. In this situation, such rapid termination kinetics do not necessarily encourage 39, 40 There is only one published case report in which buprenorphine maintenance therapy has complicated successful analgesia. 41 Buprenorphine implants deliver doses of 1-1.3 mg/ day. Further studies are required to facilitate comparisons with methadone-based OST, which traditionally outperforms SLB prescribed at a fixed and low dose (2-6 mg/day) with regard to treatment retention. 5 Findings concerning retention with implants may have been affected by the trial setting, with all trials undertaken in treatment centres, an environment vastly different to office-based buprenorphine treatment facilities. The constant surveillance and clinical contact may not serve to be a powerful predictor of how buprenorphine implants will translate into practice with less stringent monitoring. Future comparisons between SL and implantable formulations need to be conducted in office-based or community settings.
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Both long-acting transdermal 43 and depot 42, 44 formulations were investigated prior to the implant, although none received licensure. Because the clinical effects of depot injections last several weeks and cannot be rapidly terminated, they lend more toward detoxification strategies rather than maintenance. In remaining exterior to the body, transdermal therapy may not eliminate misuse or accidental exposure as effectively as an implant. Thus, implants appear the most desirable vehicle in the context of OST. Inadequate statistical power to detect differences in adverse effects between SL and implanted buprenorphine is a significant limitation to the interpretation of current safety data.
14 Whereas systemic toxicities appear consistent with well-established buprenorphine preparations, implantation and explantation procedures impart additional risks. Although rarely severe, they are an important consideration in treatment selection. Probuphine includes a boxed warning regarding the potential for implant migration, protrusion, expulsion and nerve damage associated with the insertion and removal procedures. In light of such risks, it is only available in the US through a Risk Evaluation and Mitigation Strategy, which requires providers to complete annual live training on insertion and removal procedures, and become certified before prescribing or administering implants. 45 Similar precautions would be required if the product was approved for use in Australia. The relative cost of buprenorphine implants is an important consideration not only for prescribers, but also for patients and policy makers. Although implants are more expensive than SLB over 6 months, the anticipated savings in healthcare expenditure and reduced criminality may justify the added cost. 25 In addition, implants have the potential to circumvent the misuse, diversion and inadvertent exposures attributed to existing therapies. Although diversion is difficult to assess objectively, there was no evidence of unscheduled or attempted implant removal in the clinical trials.
14, [16] [17] [18] Rosenthal et al. 18 also observed lower cocaine use among opioid-dependent patients, replicating the findings of an earlier SLB study. 46 Although the underlying mechanism remains unclear, a role for buprenorphine implants in opioid-dependent cocaine users deserves further investigation. Furthermore, Ling 32 postulated applications in specific opioid-dependent populations, including adolescents, pregnant women and patients with HIV. There are also foreseeable applications in criminal justice settings and chronic pain management. An ongoing open-label cross-over study evaluating the effect of buprenorphine implants on sleep disturbance among patients with OUD seeks to broaden the knowledge base of this emerging technology. 47 Little information exists to distinguish the clinical utility of implantable buprenorphine from existing treatment options, although it offers an additional option for treatment individualisation. 18 Implants are indicated for use in clinically stable patients, although a single unified definition of 'clinical stability' has not been ratified. What also remains unknown is the appropriate level of clinical contact and psychological support required during a 6-month course. Both are important features of addiction management and require clarification in practice. 48 Each Phase III trial saw all patients receive, at a minimum, monthly manual-guided individual drug counselling. Although semi-annual administration permits greater patient autonomy, the absence of a 'pharmacological incentive' to remain in clinical contact may hinder the delivery of vital psychosocial adjuvants and other primary healthcare interventions. The loss of clinical contact may lead to poor adherence to other treatments, such as antiretroviral therapy for HIV, which SLB can facilitate. 49 Other concerns for prescribers include the forfeiting of former dose-tapering capabilities and the questionable utility of the implants beyond 12 months.
CONCLUSION
The development of an implantable buprenorphine system represents a paradigm shift from daily dose maintenance and its associated burdens, providing further nuance in terms of treatment individualisation. However, these implants are currently only approved for the maintenance of patients who have achieved and sustained clinical stability on low-to-moderate doses of SLB. Further research into the effects of long-acting implantable OST is necessary to improve the current service delivery in Australia. Although preliminary reports are promising, the full potential of this innovative buprenorphine delivery system is yet to be determined, despite the theoretical advantages in rural and remote areas where access to OST is challenging.
